Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An observation, real-life trial to assess vildagliptin, vs oral antihyperglycaemics, in combination with oral antihyperglycaemic monotherapy in patients with type 2 diabetes mellitus inqdeuately controlled with one oral antihyperglycaemic.

Next Previous
Trial Profile

An observation, real-life trial to assess vildagliptin, vs oral antihyperglycaemics, in combination with oral antihyperglycaemic monotherapy in patients with type 2 diabetes mellitus inqdeuately controlled with one oral antihyperglycaemic.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vildagliptin (Primary) ; Antihyperglycaemics; Metformin; Sulfonylureas
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms EDGE

Most Recent Events

  • 06 Dec 2019 Results, assessing recruitment patterns on gender basis from the data of two clinical trials (VERIFY and EDGE), presented at the 2019 Congress of the International Diabetes Federation
  • 22 May 2019 Data from this study was employed to compare the outcomes obtained with general Framingham against end-point Framingham (EPF) equations; result presented at the 24th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
  • 01 Aug 2017 Results of a post-hoc analysis published in the Diabetes Therapy.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top